Many of these advances are the result of decades of work and clinical trials. Since the mid-1990s, the American Cancer ...

Inhibrx Biosciences, Inc. stays a Strong Buy with Q2 2026 ozekibart BLA catalyst, 2026 PFS data, and Ewing sarcoma updates.

A new American Cancer Society report highlights major improvements in cancer survivorship.About 70% of people in the U.S.

The American Cancer Society today released its annual “Cancer Statistics, 2026” and “Cancer Facts & Figures 2026” report — the first national snapshot of this year’s cancer trends. Experts from City ...

Men with newly diagnosed multiple myeloma are twice as likely as women to have stage III disease, with more kidney damage and ...

Medicus Pharma Ltd. (Nasdaq: MDCX) is a precision guided biotech/life sciences company focused on accelerating the clinical development programs of novel and potentially disruptive therapeutics assets ...

Rates of multiple myeloma (MM), the second most common blood cancer in the United States, are increasing and are twice as ...

Rates of multiple myeloma, the second most common blood cancer in the United States, are increasing and are twice as high in men than in women. A new study published by Wiley online in CANCER provides ...

Gastrointestinal (GI) Cancers Symposium, Dani Castillo, MD, medical oncologist, City of Hope, shared new research titled, “Impact of metastatic sites and Lauren subtype on survival outcomes of ...

Multiple myeloma, a cancer of the bone marrow, remains difficult to treat despite modern CAR T cell therapies. In recent research, a team led by Dr. Armin Rehm presents an improved immunotherapy that ...

Researchers have developed a magnetic nanomaterial that can kill bone cancer cells and support bone regeneration at the same ...

A team of cancer biologists led by Princeton’s Yibin Kang has resolved a confounding paradox about retinoids and cancer cells ...